• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Venture firms give OptiMedica $13.8 million

Article

Santa Clara, CA-Ophthalmic therapeutic device developer Optimedica Corp. raised $13.8 in capital through a Series A and B financing co-led by Kleiner Perkins Caufield & Byers and Alloy Ventures.

Santa Clara, CA-Ophthalmic therapeutic device developer Optimedica Corp. raised $13.8 in capital through a Series A and B financing co-led by Kleiner Perkins Caufield & Byers and Alloy Ventures.

"OptiMedica is committed to evolving the standards of care in ophthalmology," said David Mordaunt, PhD, OptiMedica chief executive officer. "This financing allows us to roll out technologies to support our mission, while we continue to build our world-class organization centered around our customers-the physician and, ultimately, the patient."

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.